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Abstract
siRNA therapy has great potential in humans, and its applications have been significantly
improved. The kidney is a comparatively easy target organ of siRNA therapy due to its
unique structural and functional characteristics. Here, we reviewed recent achievements
in the design, delivery, and utilization of RNAi with a focus on kidney diseases, in partic‐
ular acute kidney injury. In addition, the perspectives and challenges of siRNA therapy
such as increasing its serum stability and immune tolerance, targeting single/double/
multiple genes, cell/allele-specific delivery, time-controlled silencing, and siRNA-modi‐
fied stem cell therapy were also discussed. Finally, selecting target genes and therapeutic
time windows were addressed.
Keywords: Small interfering RNA, kidney diseases, delivery, off-target effects, compen‐
sative responses
1. Introduction
Acute kidney injury (AKI) is very common and critical in clinical practice. The incidence of
hospital-acquired AKI is increasing, and many patients require renal replacement therapy [1].
AKI significantly increases the risk of chronic renal disease, end-stage renal disease (ESRD),
and death, presenting a major burden to the patient and the health care system. Because of
high metabolic activity in handling and transporting ions, amino acids, and other small
molecules, the kidney is highly susceptible to acute injuries from lack of sufficient perfusion,
exposure to, and accumulation of nephrotoxic substances. Despite numerous clinical trials,
AKI remains a cause of significant morbidity and mortality for which there is no effective
intervention [2].
RNA interference (RNAi) is a highly conserved biological phenomenon in all eukaryotes,
including renal cells. Although RNAi naturally exists, synthetic artificial siRNA exerts similar
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effects as natural endogenous microRNA (miRNA). Both sense and antisense strands of siRNA
can be synthesized separately and annealed to form double stranded siRNA duplexes in
vitro. After the siRNA is delivered into the cytoplasm, the artificial siRNA silences the target
gene using similar biological processes as endogenous miRNA. Since the introduction of 21-
nucleotide artificial siRNAs that triggered gene silencing in mammalian cells [3], synthetic
siRNA has generated much interest in biomedical research, in which the kidney is one of
important key players. siRNA as a strategic molecule has been highly expected in the field of
innovative therapy. Because siRNA is highly efficient at gene silencing, it is possible to develop
specific siRNA-based drugs that could target any genes, including those that have unknown
pharmacological antagonists or inhibitors. Different types of synthetic siRNA have been tested
for their efficacy in various disease models, including cancer [4], autoimmune disorders [5],
cardiovascular injuries [6], and organ transplantation [7], including native and transplanted
kidney injuries [8].
As siRNA is a posttranscriptional regulator, it must first be absorbed into the target cells.
Therefore, the kidney could be an excellent target organ for siRNA therapy because it benefits
from rapid and vast blood flow physically, subsequent glomerular filtration, and tubular
absorption. In fact, the systemic administration of siRNA leads to rapid uptake by the kidney,
yielding a significant decrease of target protein expression [8]. Consequently, RNAi by siRNA
has advantages for the treatment of renal diseases due to the unique urological system [9]. In
addition, the preservation of donor kidneys before transplantation also provides a suitable
time window for the intervention of siRNA.
In this chapter, we highlighted the design and delivery of siRNA and its therapeutic effects
with a focus on kidney diseases. We also discussed future challenges of siRNA therapy,
targeting single/double/multiple genes, cell/allele specific delivery, time-controlled silence,
and siRNA-modified stem cell therapy.
2. Current principle of siRNA design
The design of potent siRNAs has been greatly improved over the past decade. The basic criteria
for choosing siRNAs include the consideration of thermodynamic stability, internal repeats,
immunostimulatory motifs, such as GC content, secondary structure, base preference at
specific positions in the sense strand, and appropriate length [10].
Chemical modifications significantly enhance the stability and uptake of naked siRNAs.
Importantly, siRNAs can be directly modified without crippling the silencing ability. Chemical
modifications have been rigorously investigated for virtually every part of siRNA molecules,
from the termini and backbone to the sugars and bases, with the goal of engineering siRNA
to prolong half-life and increase cellular uptake. The most common chemical modification
involves modifying the sugar moiety. For example, the incorporation of 2′-fluoro (2′-F), -O
methyl, -halogen, -amine, or -deoxy can significantly increase the stability of siRNA in serum.
Locked nucleic acid (LNA) has been also applied to modify siRNA. The commonly used LNA
contains a methylene bridge connecting the 2′-oxygen with the 4′-carbon of the ribose ring.
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This bridge locks the ribose ring in the 3′-endo conformation characteristic of RNA [11].
Additionally, recent studies, including ours [12], have proven the efficacy of LNA-modified
siRNA in terms of prolonged half-life in serum, but without detectable adverse effects,
suggesting that the natural RNAi machinery could accommodate a certain degree of alterations
in the chemical structure of siRNAs [13].
3. siRNA delivery
The biggest obstacle faced by siRNA therapies is the in vivo delivery of genetic materials. The
systemic delivery of synthetic siRNA has the most medical and commercial potential. This
type of delivery, however, remains a major challenge for translating siRNA from the research
to the clinic. Overcoming the delivery challenge requires effective siRNA delivery vehicles.
The virus-based delivery system, while efficient, may be fatally flawed due to raised safety
concerns, such as inducing mutations and triggering immunogenic and inflammatory
responses [14]. Therefore, extensive research had been performed to develop efficacious
nonviral delivery systems, including direct chemical modification of siRNA (as described
above) and/or optimization of delivery materials, such as liposome formulation, nanoparticle
conjugation and antibodies that target cellular moieties [14].
To date, studies on synthetic siRNA therapy have been performed in a variety of cell culture
and rodent models [15] that produced exciting results and were cost effective but failed to
faithfully mimic human diseases. Therefore, large animal models, such as porcine models, are
indispensable to compensate for the limitations of rodent models due to their greater similarity
to human beings. The investigations on siRNA conducted in our laboratory have reflected this
trend in the field [7, 12, 16].
3.1. Direct delivery of synthetic siRNA in vitro/ex vivo
The siRNA could be easily transduced into various cells for scientific research. For example,
we transfected synthetic caspase-3 siRNA in porcine proximal tubular cells (LLC-PK1) using
cationic lipid-based transfection reagent. The caspase-3 siRNA inhibited apoptosis and
inflammation in LLC-PK1 cells that were subjected to hydrogen peroxide stimulation [17]. In
addition to in vitro delivery of siRNA, ex vivo/in vivo siRNA delivery to target organs is an
indispensable step before its clinical application. If it was directly delivered into the kidneys,
siRNA could obtain higher local concentrations, which would result in improved gene
silencing efficacy. During kidney transplantation, ex vivo local delivery of siRNA into the donor
kidney is feasible because it could be facilitated by the unique structure of the kidney and the
characteristics of kidney transplantation. We utilized an ex vivo isolated porcine kidney
reperfusion system to assess the efficacy of naked caspase-3 siRNA. The caspase-3 siRNA was
directly infused into the renal artery (locally) and autologous blood perfusate (mimic systemic
delivery) before 24-h cold storage (CS), followed by a further reperfusion for 3 h. The results
demonstrated that the caspase-3 siRNA improved ischemia reperfusion (IR) injury with
reduced caspase-3 expression and apoptosis, better renal oxygenation, and acid–base homeo‐
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stasis [16]. These promising proof-of-principle observations provide valuable guidance for
further development before siRNA used in clinical practice.
3.2. Local or systemic delivery of siRNA in vivo
Delivery of siRNA via ex vivo route can be applied in donor kidneys, but most renal diseases
need in vivo delivery. Based on the anatomical and physiological characteristics of the kidney,
local delivery can be achieved through several routes: (1) renal artery, first targeting the
glomeruli or tubules [18, 19]; (2) renal vein, predominately targeting tubulointerstitium [20];
(3) intraureteral, administered into the renal pelvis and interstitium [21]; and (4) subcapsular
administration, achieves intraparenchymal silencing [22]. Due to the rich blood flow through
the glomeruli, siRNA injection via the renal artery followed by electroporation could silence
specific genes in the glomeruli, such as TGF-β1, which subsequently ameliorates matrix
expansion in an experimental glomerulonephritis model [18].
We then used naked caspase-3 siRNA in a porcine kidney autotransplant model for the first
time. The left kidney was retrieved from mini pigs and was infused with University of
Wisconsin solution, with or without 0.3 mg of naked caspase-3 siRNA, via the renal artery,
which was followed by renal artery and renal vein clamping for 24-h cold storage (CS,
mimicking donor kidney preservation before transportation in clinic). After right nephrecto‐
my, the left kidney was autotransplanted into the right nephridial pit for 48 h without systemic
siRNA treatment (Figure 1). The expression of caspase-3 mRNA and active caspase-3 protein,
as well as its precursor, was downregulated by siRNA in the post-CS kidney. In the siRNA
preserved posttransplant kidney, however, caspase-3 precursor was further decreased while
caspase-3 mRNA, and its activated subunits were upregulated, which resulted in increased
apoptosis and inflammation. This study indicated that the naked caspase-3 siRNA was
effective for cold preservation but was not effective at protecting posttransplant kidneys,
which may be due to systemic compensative responses overcoming local effects. Therefore, to
overcome the systemic response and to prolong the therapeutic time window, we subsequently
utilized a novel, serum-stable caspase-3 siRNA, both locally as before and systemically via a
pretransplantation intravenous injection, and observed the animals for up to 2 weeks post‐
transplantation. The effectiveness of the novel caspase-3 siRNA was confirmed by downre‐
gulated caspase-3 mRNA and protein in the post-CS and/or posttransplant kidneys, as well as
reduced apoptosis and inflammation. More importantly, renal function, associated with active
caspase-3, HMGB1, apoptosis, inflammation, and tubulointerstitial damage, was improved by
this novel, serum-stable caspase-3 siRNA [12].
It has also been revealed that an injection of a single-dose Fas siRNA through the renal vein
post ischemia provided a survival advantage in a murine IR model, which was due to the
antiapoptosis and antiinflammation effects of the Fas siRNA [20]. Unilateral ureteral obstruc‐
tion (UUO) is a well-established model for tubulointerstitial fibrosis. Xia et al. injected the
siRNA of heat shock protein 47 once via the ureter at the time of UUO preparation, leading to
significantly reduced fibrosis-related protein expression and a remarkable alleviation of the
accompanying interstitial fibrosis [21]. Subcapsular administration is still used in some
experiments due to its unique advantages, although it requires an invasive procedure and has
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limitations in clinical practice. Cuevas et al. reported that an infusion of DJ-1 (an antioxidant)-
specific siRNA into the subcapsule silenced DJ-1 expression in the renal cortex and increased
ROS production [22].
Systemic delivery is a common and convenient clinical practice, although current clinical trials
using siRNAs are almost directly administered to the target site, such as the nostril, eye, and
lung, thereby avoiding the complexity of systemic delivery [23]. The most common method of
systemic siRNA delivery is a hydrodynamic intravenous injection with hydraulic pressure to
assist siRNA cell entry. However, the pharmacokinetic metabolism of siRNA is more compli‐
cated during systemic delivery because siRNAs can be rapidly degraded by nucleases in the
serum and cleared by the kidney and liver. To enhance the in vivo efficacy of siRNA treatment,
a variety of approaches have been attempted for both siRNA itself and delivery techniques
[22–24], as mentioned above.
Due to its anatomical and physiological characteristics, the kidney is the most preferable target
organ of systemic siRNA administration. siRNA access to the kidney is thought to be depend‐
ent on the filtration and reabsorption functions of the kidney. Proximal tubule cells (PTCs) are
Figure 1. Schematic drawing showed a series of our studies using caspase-3 siRNA. The caspase-3 siRNA was first
used to protect porcine renal tubular epithelia cells against hydrogen peroxide-induced injury [17]. The renoprotection
of naked caspase-3 siRNA with the same sequences was further validated in a porcine ex vivo isolated reperfusion
model and showed that the siRNA was effective for cold preservation [16], but not in autotransplanted kidneys with‐
out systematic siRNA treatment [7, 12, 16]. Finally, the chemically modified siRNA of caspase-3 via locked nucleic acid
stabilized the siRNA in serum and significantly protected autotransplanted kidneys [7, 12, 16].
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the primary site for rapid and extensive endocytic uptake of siRNA within the kidney
following glomerular filtration. In an AKI model, naked synthetic siRNA targeting p53 that
was intravenously injected 4 h after renal ischemic injury significantly reduced upregulated
p53 expression and protected both the PTCs and kidneys [25]. In another study performed by
Zheng et al., siRNA was systematically injected to target complement 3 (C3) and caspase-3 in
a murine renal IR injury model. The results showed that the level of serum creatinine and blood
urea nitrogen was significantly decreased in the siRNA-treated mice [26]. As most of AKI may
be not associated with renal surgery, the systemic siRNA delivery might be a desirable
approach. However, for kidney transplantation, in which IR injury is inevitable, local siRNA
delivery via any above-mentioned method is feasible and more effective.
3.3. Cell-specific delivery
As proposed by precision medicine, individual person should receive customized healthcare
including diagnosis and intervention. The dysfunctional cells are the true targets for siRNA
delivery. For instance, it is known that p53 in PTCs promotes AKI, whereas p53 in other tubular
cells does not [27]. It is also expected that apoptosis-inducing siRNA should be directly
delivered into tumor cells rather than the surrounding normal cells. Therefore, the cell-specific
delivery method is our key point in the next generation of siRNA development.
Recently, antibody conjugation technology has made tumor-targeting drug delivery systems
available. The conjugate can be regarded as a “guided molecular missile” that specifically
targets unique antigens [28]. Inspired by cancer therapy strategies, siRNAs have also been
“packed” to be delivered to target organs, even cells. Recently, a type of asymmetric liposome
particle (ALP) has been developed, which highly efficiently encapsulates siRNA without
nonspecific cell penetration. The ALPs protected siRNA from ribonuclease degradation. ALPs
without any surface modification elicited almost no uptake into cells, while the polyarginine
peptide surface-modified ALPs induced nonspecific cell penetration [29]. Leus et al. delivered
siRNA targeting vascular cell adhesion molecule-1 (VCAM-1) into inflammation-activated
endothelium using anti-VCAM-1-SAINTPEGarg formulated with additional 2 mol% DOPE-
PEG2000 in vivo. The antibody recognizes VACM-1, which can create specificity for inflamma‐
tion activated endothelial cells. The siRNA homed to VCAM-1 protein expressing vasculature
in TNF-α-treated mice without any kidney and liver toxicity [30]. These results represent great
progress in siRNA delivery system development. Antibody-mediated specific recognition
rather than virus-mediated recognition may be a mainstream in the future.
3.4. Allele-specific RNAi
RNAi, in addition, discriminates between two sequences only differing by one nucleotide
conferring a high specificity of RNAi for its target mRNA. This property was used to develop
a particular therapeutic strategy called “allele-specific RNAi” devoted to silence the mutated
allele of genes causing dominant inherited diseases without affecting the normal allele.
Therapeutic benefit was now demonstrated in cells from patients and animal models, and
promising results of the first phase Ib clinical trial using siRNA-based allele-specific therapy
were reported in pachyonychia congenita, an inherited skin disorder due to dominant
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mutations in the keratin 6 gene [31]. The allele-specific siRNA silencing of the mutant keratin
12 allele was also applied in corneal limbal epithelial cells grown from patients with Mees‐
mann’s epithelial corneal dystrophy [32, 33]. It has also been shown that modified siRNAs
conferring allele-specific silencing against disease-causing ALK2 mutants found in fibrodys‐
plasia ossificans progressiva, without affecting normal ALK2 allele [34].
3.5. Delivery of siRNA using a cargo system
Although lentivirus vectors as vehicles together with liposome reagents are widely applied in
the transduction of siRNA, nanoparticle systems have emerged in last few years as an
alternative carrier for advanced diagnostic and therapeutic applications. The nanotechnology
offers many merits and overcomes the range of challenges/barriers summarized in the
previous section, such as the bioavailability and biodistribution of therapeutic agents. Recent
reports have demonstrated that the kidney, the glomerulus especially, is a readily accessible
site for nanoparticles. Zuckerman at al. intravenously administered nanoparticles containing
polycationic cyclodextrin and siRNA/CDP-NPs, most of which deposited in the glomerular
mesangial areas. Furthermore, the cultured mouse and human mesangial cells could rapidly
internalize siRNA/CDP-NPs. This process could be accelerated by attaching targeting ligand
mannose or transferrin to the nanoparticle surface [35].
Complex nanoparticles, especially cationic polyplexes/lipoplexes and liposomes, dominat‐
ed the scene in the early days of RNAi therapeutic development. Their main advantage lies
in their endosomal release activity and their ability to concentrate multiple RNAi triggers
in  one  particle  [36].  Forbes  and  Peppas  cross-linked  polycationic  nanoparticle  formula‐
tions using ARGET ATRP or UV-initiated polymerization. The advantage of this method
is  the  one-step,  one-pot,  and surfactant-stabilized monomer-in-water  synthesis,  which is
simpler and faster compared with traditional complicated multistep techniques involving
toxic organic solvents [37].
Regardless of how much each mechanism plays in the transport of the drug, cell entry remains
a focus for drug design and discovery. An exciting and relatively new approach to transporting
pharmaceutical agents into cells is making use of cell-penetrating peptides (CPPs). CPPs are
relatively short peptides, typically less than 30 amino acids, and could be vectors for the
delivery of genetic and biologic products. CPPs provide a safe, efficient, and noninvasive mode
of transport for various cargos into cells [38]. Recently, van Asbeck et al. discovered that CPP/
siRNA complexes with the most negative zeta-potentials in serum were the most resistant to
siRNA release over a 20-h incubation period compared to less negatively charged complexes
[39]. They also found that the zeta-potential of CPP/siRNA complexes in serum did not
correlate with improved cellular association, which might demonstrate the importance of
serum proteins or CPP conformation on the ability of CPP/siRNA complexes to associate with
the cell membrane. Huang et al. designed a bifunctional peptide named RGD10-10R, by which
siRNA was delivered in vitro and in vivo. Because of their electrostatic interactions with
polyarginine (10R), negatively charged siRNAs were readily complexed with RGD10-10R
peptides, forming spherical RGD10-10R/siRNA nanoparticles. This is also a novel siRNA
delivery tool [40].
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Gemini or dimeric lipids (GCLs) are a recent type of amphiphilic molecules that contain two
polar headgroups linked by a rigid or flexible spacer that may be hydrophobic or hydrophilic.
As each headgroup has a hydrophobic moiety, GCLs may be considered as two conventional
monomeric surfactants connected by a spacer group [41]. GCLs have been proved as promising
candidates to transfect nucleic acids in gene therapy. The molecular structure of the GCLs
offers a high number of alternatives to develop and to improve their capability as transfecting
agents.
4. siRNA therapy in AKI
To date, siRNA therapy has been successfully applied in a variety of acute kidney injuries. IR
injury is the primary cause of AKI, particularly during kidney transplantation, in which the
kidney is exposed to hypoxia and experiences a series of oxidative, inflammatory and apoptotic
responses [42, 43]. Consequently, specific siRNAs targeting critical molecules that are involved
in the processes of oxidation, inflammation, and apoptosis have been developed.
Caspase-3, which mediates apoptosis and inflammation, is upregulated by IR injury. Multiple
pharmacological interventions against caspase-3, including enzyme inhibitors and genetic
modification, have been investigated. In recent years, our group studied the delivery and
efficacy of caspase-3 siRNA in in vitro, ex vivo, and in vivo kidney injury models. The synthetic
caspase-3 siRNA was initially tested in porcine PTCs (LLC-PK1), with or without hydrogen
peroxide (H2O2) stimulation. Apoptotic cells and activated IL-1β protein expression were
significantly reduced by the caspase-3 siRNA, with improved cell viability [17]. This outcome
led to siRNA application in an isolated organ perfusion system, as described above, and the
efficacy of caspase-3 siRNA was further proven, in terms of silenced caspase-3 mRNA and
protein expression, attenuated inflammation and apoptosis, and improved renal function and
histology [16].
The porcine kidney preserved by caspase-3 siRNA was then autotransplanted in a 2-day
model. However, the transplanted kidney was not protected without systemic treatment of
the recipient. Moreover, new serum-stabilized caspase-3 siRNAs were applied locally in
kidney preservation and intravenously in recipient in a 2-week autotransplant model. The
transplanted kidneys were protected without significant off-target effects. These serials of step-
by-step studies provided promising evidence to support siRNA treatment to be further applied
in clinic.
p53, another pivotal protein in the apoptotic pathway, has been identified as a mediator of
transcriptional responses to IR injury [44]. Molitoris et al. revealed that intravenously injected
p53 siRNA attenuated ischemic and cisplatin-induced AKI [25]. Fujino et al. also tested the
efficacy siRNA targeting p53 via transarterial administration siRNA injected into the left renal
artery immediately after ischemia improved tubular injury and downregulated GSK-3β
expression [45]. In a diabetic mouse model, p53 inhibition by siRNA also reduced ischemic
AKI [46].
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Silencing of other important transcription factors or immunity related receptors using siRNAs
have also been studied. Renal IR injury and inflammation are related to postsurgical healing
and both processes can be influenced by toll-like receptor (TLR) signals. Effective TLR9
silencing by siRNA decreases renal cell apoptosis, mitigates AKI severity, and increases the
mice survival [47]. NF-κB, a pro-inflammatory transcription factor induced by TLR and other
signals, plays a key role in AKI. NF-κB activation depends on the activation of the inhibitor of
κB kinase β (IKKβ). Wan et al. demonstrated that silencing IKKβ using siRNA diminished
inflammation and protected the kidneys against IR injury [19]. These studies clearly demon‐
strate the therapeutic potential of siRNA-induced silencing of key AKI mediators, which are
activated and involved in the pathways of apoptosis, inflammation, immunity, etc.
5. Off-target side effects and toxicities of siRNA
The siRNA has been likened to a “magic bullet” due to this potency and specificity, but off-
target side effects and toxicities create additional challenges for researchers. The induction of
various side effects may be caused by unexpected perturbations between RNAi molecules and
cellular components. The off-target effects of siRNA were first reported by Jackson and
colleagues in 2003 [48]. Broadly speaking, off-target effects can be siRNA specific or nonspe‐
cific. The former are caused by limited siRNA complementarity to nontargeted mRNAs. The
latter, resulting in immune- and toxicity-related responses, are due to the construction of the
siRNA sequence, its modification, or the delivery vehicle.
The off-target effects associated with siRNA delivery fall into three broad categories: (1)
miRNA-like off-target effects, referring to siRNA-induced sequence-dependent regulation of
unintended transcripts through partial sequence complementarity to their 3′UTRs; (2)
inflammatory responses through the activation of TLR triggered by siRNAs and/or delivery
vehicles (such as cationic lipids and viruses); and (3) widespread effects on miRNA processing
and function through the saturation of the endogenous RNAi machinery by exogenous siRNAs
[49, 50].
5.1. miRNA-like off-target effects
The siRNAs and miRNAs share similar machinery downstream of their initial processing.
Using several different siRNAs targeting the same gene, microarray profiling showed that each
siRNA produced a unique, sequence-dependent signature. Sequence analysis of off-target
transcripts revealed that the 3′ UTR regions of these transcripts were complementary to the 5′
end of the transfected siRNA guide strand [48]. It is now understood that for the off-targeting
effects to occur, a perfect complementarity between the seed region of the antisense strand
such as nucleotide positions 2–7 or 2–8 and the 3′ UTR of the transcript is necessary [49, 51].
Silencing the set of original off-target transcripts could be induced by base mismatches in the
5′ end of siRNA guide strands. However, a new set of off-target transcripts within 3′ UTRs
that were complementary to the mismatched guide strand could be generated [49].
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RNAi regulation by miRNAs involves partial complementarity between the targeting RNA
and miRNA. Because miRNAs cause gene silencing through mRNA degradation and trans‐
lation inhibition, the siRNA-mediated off-target effects may also be acting at two levels. For
this reason, there should be greater emphasis on improving siRNA design as well as moni‐
toring gene and protein levels following RNAi therapy to account for any off-target effects.
5.2. Recognition and stimulation of the innate immune system
The recognition and stimulation of the immune system arenonspecific off-target effects of
siRNA therapy. The RNA-sensing pattern recognition receptors (PRRs), localized in endo‐
somes, are the most important components of the innate immune system. The responses of
PRRs to siRNAs are either TLR-mediated or non-TLR-mediated. The PRR responses are also
associated with siRNA sequence-specific side effects and have recently attracted many
attentions from researchers [52]. RNA-sensing TLRs (TLR3 and TLR7) are predominantly
located intracellularly and recognize nucleic acids released from invading pathogens. The non-
TLR-mediated innate immune responses triggered by siRNA binding are linked to RNA-
regulated expression of protein kinase (PKR) and retinoic acid inducible gene 1 (RIG1), which
further induce caspase-3 and NF-κB expression, respectively. The activation of PRRs generates
excessive cytokine release and subsequent inflammation [53].
Based on this second type of off-target RNAi effects, our group further investigated the
mechanism of how short-acting caspase-3 siRNA impaired posttransplanted kidneys. The
results suggested that the amplified inflammatory responses in caspase-3 siRNA preserved
autotransplant kidneys were associated with TLR3, TLR7, and PKR activation, which may be
due to systemic compensative responses, although persistent actions initiated by short-acting
caspase-3 siRNA cannot be completely excluded [54]. Other studies have also indicated that
the horseshoe-like structure of TLR3 facilitates dsRNA recognition [55, 56]. Interactions
between TLR3 and dsRNA were originally reported in 2001 when TLR3-deficient mice
exhibited reduced immune responses to dsRNA viruses [57].
Several studies have demonstrated that the immune response to siRNAs is cell type-dependent
due to the selective expression of TLRs. siRNAs stimulate monocytes and myeloid dendritic
cells through TLR8 to produce proinflammatory cytokines, or activate plasmacytoid dendritic
cells through TLR7 to produce type I interferons [58–60]. In addition, the volume of hydrody‐
namic naked siRNA delivery influences immune activation. Rácz et al. compared the immune
responses induced by 50 μg siRNA dissolved in either low-volume (1 mL/mouse) or high-
volume (10% of body weight, 2.5 mL/mouse in average) physiological salt solution delivered
in vivo. Low-volume hydrodynamic injection induced slight alanine aminotransferase (ALT)
elevation and mild hepatocyte injury, whereas high-volume hydrodynamic injection resulted
in higher ALT levels and extensive hepatocyte necrosis. High-volume hydrodynamic injection
also led to a time-dependent slight increase in IFN-related gene expression [61]. Collectively,
these studies suggest that there is a need for improving siRNA design, establishing experi‐
mental controls and carefully interpreting results.
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6. From bench to bedside: Clinical trials
The numbers of RNAi-based preclinical studies and clinical trials have grown over the past
several years. To date, there have been 27 registered clinical trials using siRNA worldwide.
These studies include retinal degeneration, dominantly inherited brain and skin diseases, viral
infections, respiratory disorders, metabolic diseases, and of particular note, kidney diseases.
In 2011, Quark Pharmaceuticals completed a phase I, randomized, double-blind, dose
escalation, safety, and pharmacokinetic study (NCT00554359) on QPI-1002, also designated
I5NP, which was a synthetic siRNA that temporarily inhibits p53 expression that is in early
development for acute kidney failure therapy. I5NP is the first siRNA to be systemically
administered in humans. Based on the preclinical data obtained from animal models, the
siRNA was intravenously injected within 4 h to bypass surgery patients. Pharmacokinetic data
were collected during the first 24 h, and safety and dose-limiting toxicities were monitored
until hospital discharge and 6–12 months after surgery. Recently, Quark initiated a subsequent
clinical trial to determine whether a single administration of I5NP can prevent delayed graft
function in kidney transplant recipients. Data from this study will be used to identify I5NP
doses for follow-on efficacy studies (NCT00802347). Another ongoing phase I trial investigat‐
ing solid tumors, including Renal cell carcinoma (RCC), was conducted by Calando Pharma‐
ceuticals. The investigators used CALAA-01, whose active ingredient is a type of siRNA, to
inhibit tumor growth and/or reduce tumor size. This siRNA inhibits the expression of the M2
subunit of ribonucleotide reductase and resists nuclease degradation by using a stabilized
nanoparticle that targets tumor cells (NCT00689065).Besides, there is an ongoing study, in
which patients with melanoma, kidney cancer, pancreatic cancer, or other solid tumors that
are metastatic or cannot be removed by surgeryare treated by APN401, siRNA-transfected
autologousperipheral blood mononuclear cells.These cells were modified by siRNA targeting
factors inhibiting the killing ability of immune cells in vitro and transfused back into the body,
in order to kill more cancer cells (NCT02166255, the above clinical trials can be found at
ClinicalTrials.gov, Table 1).
Study Target/siRNA drug Status Disease
NCT00554359 I5NP Phase I, completed Kidney injury; acute renal failure
NCT00802347 I5NP Completed Delayed graft function in kidney
transplantation
NCT00689065 CALAA-01 Phase I, terminated Solid tumor cancers including RCC
NCT02166255 APN401 Phase I, recruiting Melanoma, kidney cancer, pancreatic
cancer, or other solid
Table 1. Clinical trials of siRNA therapy in kidney diseases.
7. Perspectives and challenges
Despite the enormous potential advantages of siRNA therapy, additional research must be
performed before its large-scale clinical application.
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7.1. Target gene selection
Genome-wide or pathway-specific siRNA libraries have become available using high-
throughput screening approaches. Establishing in vitro prescreening leads to signaling
pathway prediction and target validation in in vivo renal disease. However, choosing one or a
set of reasonable target genes is the key for designing specific siRNA treatments. The patho‐
physiological changes during kidney disease, like any other disease, refer to a complex gene
and protein regulation network. For example, the network that exists during kidney trans‐
plantation involves the original conditions of the donors and the interactions between the
donor kidneys and the recipients, which could direct the progression, as well as the recovery,
of the injury. Fortunately, transcriptome measurements of the transplanted kidney may
provide a comprehensive understanding of gene regulation and would be beneficial for target
gene selection.
Mueller et al. analyzed the transcriptome of postreperfusion implant biopsies in living donors
(LD) and deceased donors (DD). Hundreds of mRNAs were identified that predicted delayed
graft function [62]. In a recent prospective study using human posttransplant kidney biopsies,
20 mRNAs and two miRNAs were identified as molecular signatures of AKI. Elevated
secretory leukocyte peptidase inhibitor in AKI allografts was validated and miR-182-5p was
identified as a molecular regulator [63]. These genes could be used as potential targets of siRNA
therapy. We recently identified 3 times more differentially expressed genes in renal allograft
biopsies between living donors and cadaveric donors at 30 min than 3 months posttransplan‐
tation. The majority of these differentially expressed genes are responsible for acute responses
at 30 min, but also involved in inflammation, nephrotoxicity, and proliferation at 3 months.
These divergent transcriptome signatures between two types of donors might be linked with
not only the initial injury of the donors, but also the immune responses of the recipients.
Another method for selecting target genes is by identifying their translation product proteins.
To find a single or a set of crucial proteins involved in kidney allograft rejection, Wu et al.
explored potential transcriptional factors and regulation networks in 352 kidney transplant
recipients, of which 85 suffered from acute rejection (AR). The results demonstrated that the
dominant processes and responses were associated with inflammation and complement
activation in AR. A number of transcription factors were identified in AR patients, including
NF-κB, signal transducer, and activator of transcription (STAT) 1 and STAT3 [64]. Their recent
study further revealed inflammation-derived kidney allograft injury, such as AR, chronic
rejection, and impaired renal function without rejection. Wu et al. 12 common proteins and 11
level-specific proteins from the phenotype-related protein–protein interaction networks [65].
These potential biomarkers also provide valuable targets for siRNA design relating to the
treatment of transplant-related injury.
7.2. Timely application
Compared with shRNA, an advantage of siRNA for AKI therapy is time-controlled, transient
treatment. Silencing the target gene for a short time or a long time should be assessed before
RNAi application. The silenced genes may be multifunctional according to the surrounding
milieu. For example, caspase-3, generally considered an executor in cellular apoptosis, should
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be inhibited in injured tissues. However, it is also a loyal scavenger in malignantly transformed
cells, which could be an unavoidable side effect in any caspase-3-targeting siRNA therapy. For
AKI, siRNA ineffectiveness is needed after the therapeutic time window. Additionally, siRNA
application avoids intracellular traffic. In certain circumstances, shRNA delivery could be
harmful to the organ or even fatal.
A study from Grimm et al. investigated the long-term effects of sustained high-level shRNA
expression in the livers of adult mice. An evaluation of 49 distinct adeno-associated virus/
shRNA vectors, with unique lengths and sequences that were directed against six targets,
showed that 36 vectors resulted in dose-dependent liver injury, with 23 ultimately causing
death. The observed morbidity was associated with the downregulation of liver-derived
miRNAs, indicating possible competition of the latter with shRNAs (through saturation of the
endogenous RNAi machinery by the exogenous siRNAs) for the limited cellular factors
required for the processing of various small RNAs [66]. Therefore, controlling intracellular
shRNA expression levels will be imperative, but siRNA would not influence the endogenous
process of RNA degradation mediated by miRNAs.
7.3. siRNA targeting single, double or multiple genes
The knockdown of two or more genes simultaneously using siRNA cocktail has been recently
reported. Many applications of siRNA cocktail have demonstrated significant benefits
compared with siRNA targeted to a single gene, particularly in anticancer and antiviral therapy
[67, 68]. A high concentration of individual siRNAs may represent the key off-target effect in
terms of competition for endogenous miRNA biogenesis machinery. Therefore, the other
advantage of siRNA cocktail is the relatively low concentration of each siRNA, which may also
reduce off-target signatures without sacrificing silencing potency [69].
7.4. Cell-specific siRNA targeting
We have showed that the apoptosis of different types of cells leads to different outcomes. For
instance, the apoptosis of inflammatory cells is associated with inflammation clearance and
tissue remodeling, whereas the apoptosis of renal parenchymal cells is link to tubular atrophy
and renal fibrosis. Therefore, using the genetic material such as siRNA targeting specific cell
at particular time frame is crucial to achieve high efficacy of treatment in AKI and also avoid
site-effects [12, 54].
It is still challenging to administrate siRNA cell specifically, but it is feasible as there were a
few studies showed delivering siRNA into liver cells and antigen-presenting cells [70–72] using
carbon nanotubes and mannose-conjugated liposomes. In addition, surface pegylation and
cell-specific targeting ligands incorporation in the carriers may improve the pharmacokinetics,
biodistribution, and siRNA selectivity. Choosing appropriate siRNA carriers has to consider
the safety, effectiveness, ease of manufacturing, off-target effects [12], and innate immune
responses. Of course, the efficacy of siRNA is still a most important factor dominating the
selection of its carriers [54].
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7.5. siRNA-modified stem cell therapy
Mesenchymal stem cell (MSC) transplantation has attracted much attention in cell therapy in
different organ systems such as myocardial infarction. One of the limitations is the poor
survival of grafted cells in the ischemic microenvironment. To tackle this issue, a novel siRNA-
mediated prolyl hydroxylase domain protein 2 (PHD2) silencing system has been developed
based on arginine-terminated generation 4 poly (amidoamine) nanoparticles. This system, for
the first time, exhibited effective and biocompatible siRNA delivery and PHD2 silencing in
MSCs in vitro. After transplant PHD2 siRNA-modified MSC in myocardial infarction models,
MSC survival and paracrine function of IGF-1 were enhanced significantly in vivo, with
decreased cardiomyocyte apoptosis, scar size, and interstitial fibrosis, and increased angio‐
genesis in the diseased myocardium, which ultimately attenuated ventricular remodeling and
improved heart function. This study demonstrated that a great potential of siRNA-modified
stem cells in therapeutic applications, which, of course, might be used in AKI [73].
8. Conclusions
The kidney is a comparatively easy target organ for siRNA therapy due to its unique structural
and functional characteristics. siRNA intervention is effective, feasible, and has great potential
for fighting against kidney diseases. For the next-generation siRNA development, cell-specific
precise delivery should be pursued. Although the safety of siRNA therapy has been proven
by rapidly emerging clinical studies, off-target and compensative responses still need be
overcome via various modification strategies. The time for realizing the therapeutic potential
of RNAi has come because optimized siRNA therapy, in conjunction with advanced genetic
screening technologies, could facilitate timely and specific treatment of kidney as well as other
organ diseases in the near future.
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